Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

AbbVie

Moderna

The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that provide life-changing drugs.

Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential

Novo Nordisk is in a buy zone after a 39% gain year to date. The anti-obesity drug market is expect to grow to $4.4 billion by 2032.

Obesity Drug Leader In Buy Zone After Huge Gains

Netflix

Netflix and Novo Nordisk are just two names on this smorgasbord of stocks setting up or soaring past new buy points.

Netflix, Novo Nordisk Join 3 Fashionable Breakouts; 4 IPOs In Focus

A couple of new scientific studies on Ozempic were just published. Both indicate that the medicine could be useful in treating addiction.

Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock

Advanced Micro Devices

Eli Lilly

NVIDIA

Taiwan Semiconductor Manufacturing

As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.

Beyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight

Designed to celebrate diverse, unique portrayals of individuals who partner with their healthcare professional to change the course of their weight-management journey, while educating on the clinical data of Wegovy® Reflects the power of personal journeys to address stigma, and the importance of us all working together to address excess weight and treat obesity PLAINSBORO, N.J. , June 3, 2024 /PRNewswire/ -- Novo Nordisk today launched The Power of Wegovy®, a new national campaign.

Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®

Bristol-Myers

Chevron

Enbridge

Enterprise Products Partners

Energy Transfer LP Unit

Kinder Morgan

National Retail Properties

Realty Income Corp

Pfizer

Prologis

Rexford Industrial Realty

W. P. Carey

Exxon Mobil

Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and income investors can potentially achieve a high level of success by buying quality undervalued companies that pay dividends. In this article, I highlight high-yielding names in REITs, Energy, and Healthcare that I find attractive at present.

Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks

Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results.

Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030

The vast majority of patients using GLP-1 agonists such as Ozempic and Wegovy are being treated for diabetes or chronic weight management. GLP-1 medications are believed to have further applications, and Wegovy just gained FDA approval to treat people with heart disease.

Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run

Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.

This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors

Intuitive Surgical

Universal Health Services

Vertex Pharmaceuticals

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Novo Nordisk stock traded close to a buy point Friday afternoon as shares bounced from their 21-day line this week.

Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?

Goldman Sachs predicts that the global market for obesity treatments will surge to $130 billion by 2030, up from an earlier estimate of $100 billion. This revised forecast reflects the growing demand for anti-obesity medications, particularly those based on GLP-1 receptor agonists, which mimic a hormone that helps regulate appetite and blood sugar levels.

Fat profits from obesity? Goldman Sachs forecasts weight loss market will hit $130bn by 2030

Novo Nordisk has filed nine lawsuits against medical spas, wellness clinics and pharmacies for allegedly selling impure products claiming to contain semaglutide, the active ingredient in its weight loss and diabetes drugs Wegovy and Ozempic, the latest legal dispute between the Danish drugmaker and companies that claim to sell semaglutide.

Ozempic-Maker Novo Nordisk Sues Pharmacies And Weight Loss Clinics For Allegedly Selling Impure Drugs

Novo Nordisk said on Thursday it had sued nine more medical spas, wellness clinics and pharmacies in the U.S. for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss drug Wegovy.

Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs

Catalent

Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.

Catalent stockholders approve deal with Novo Holdings

Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs Wegovy and Ozempic, following the launch of an investigation into the drugs led by U.S. Senator Bernie Sanders.

Novo Nordisk blames middlemen in U.S. healthcare system for high prices of weight loss drugs Wegovy and Ozempic

Novo Nordisk said it retains about 60% of the list price of its popular diabetes and obesity drugs - Ozempic and Wegovy - after rebates and fees paid to middlemen in the United States, according to a Bloomberg report on Tuesday.

Novo blames US health system after criticism over Wegovy price, Bloomberg reports

As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly , increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.

Weight-loss drug forecasts jump to $150 billion as supply grows

Arcellx

Agenus

BridgeBio Pharma Inc

Coya Therapeutics Inc

CRISPR Therapeutics

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.

7 Biotech Stocks to Put on Your Breakthrough Radar

United Therapeutics

The biotech sector is a hotbed of innovation, making the case for the best biotech stocks to buy in May. However, not all groundbreaking companies are worth the attention given the immense risks.

3 Underappreciated Biotech Stocks to Buy Now: May 2024

Novo Nordisk is a Danish pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. The company's main source of income comes from diabetes treatments, including insulin products and GLP-1 receptor agonists. Novo Nordisk has a long-term growth strategy, focusing on the development of new treatments for cardiovascular diseases, Alzheimer's, Parkinson's, and other emerging markets.

Novo Nordisk: Considerable Growth Beyond Ozempic

Novo Nordisk has been a dominant stock lately thanks to Ozempic, and to a lesser extent, Wegovy. The weight-loss market will, however, get a lot more crowded over the next 10 years.

Where Will Novo Nordisk Be in 10 Years?

Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.

Wegovy users have less kidney-related health problems, analysis of Novo study finds

Badger Meter

Cintas Corp

Erie Indemnity

W.W. Grainger

Buying stocks at record highs doesn't necessarily mean lower returns, and can actually lead to higher returns in the short term. Valuations matter, but the metric used to evaluate them is important. Cash-adjusted valuations provide a more accurate picture of a company's value. Dividend aristocrats are modestly undervalued, but these five are 50% historically overvalued, a challenging level that has led to long bear markets and poor returns for many years.

5 Dividend Aristocrats To Sell Before It's Too Late

News for Novo Nordisk Stock (NVO)